Benzinga's Top Pre-Market Losers

Halozyme Therapeutics HALO dipped 20.68% to $6.75 in the pre-market session after the company provided update on ViroPharma Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase. Entropic Communications ENTR shares fell 16.48% to $3.70 in the pre-market trading after the company reported Q2 results. Benchmark downgraded Entropic from “buy” to “hold.” Reliv International RELV shares dropped 15.57% to $3.09 in pre-market trading after the company posted a Q2 net loss of $214,000, versus a year-ago net income of $103,000. NII Holdings NIHD dipped 6.94% to $6.70 in the pre-market session on second-quarter results.